Literature DB >> 19127107

Human telomerase reverse transcriptase (hTERT): a target molecule for the treatment of cisplatin-resistant tumors.

Yuk Pheel Park1, Kwang Dong Kim, Seong Ho Kang, Do Young Yoon, Joo Won Park, Jong Wan Kim, Hee Gu Lee.   

Abstract

BACKGROUND: Human telomerase reverse transcriptase (hTERT) is a catalytic enzyme that is required for telomerase activity (TA) and cancer progression. Telomerase inhibition or inactivation increases cellular sensitivity to UV irradiation, DNA-damaging agents, the tyrosine kinase inhibitor, imatinib, and pharmacological inhibitors, such as BIBR1532. hTERT is associated with apoptosis. Some patients show drug-resistance during anti-cancer drug treatment and the cancer cell acquire anti-apoptotic mechanism. Therefore, we attempted to study correlation between hTERT and drug-resistance.
METHODS: To study the correlation between protein level and activity of hTERT and drug-resistance, Western blotting and telomerase repeat amplification protocol (TRAP) assays were performed. To investigate whether hTERT contributes to drug resistance in tumor cells, we transiently decreased hTERT levels using small interfering RNA (siRNA) in T24/R2 cells.
RESULTS: hTERT knockdown increased Bax translocation into the mitochondria and cytochrome C release into the cytosol. Caspase inhibitors, especially Z-VAD-FMK, rescued this phenomenon, suggesting that the stability or expression of hTERT might be regulated by caspase activity.
CONCLUSIONS: These data suggest that hTERT might be a target molecule for drug-resistant tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19127107     DOI: 10.3343/kjlm.2008.28.6.430

Source DB:  PubMed          Journal:  Korean J Lab Med        ISSN: 1598-6535


  6 in total

1.  Inhibition of autophagy enhances cisplatin-induced apoptosis in the MG63 human osteosarcoma cell line.

Authors:  Zhicai Zhang; Zengwu Shao; Liming Xiong; Shuhua Yang
Journal:  Oncol Lett       Date:  2015-09-10       Impact factor: 2.967

2.  Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Authors:  Orit Uziel; Einat Beery; Vladimir Dronichev; Katty Samocha; Sergei Gryaznov; Lola Weiss; Shimon Slavin; Michal Kushnir; Yardena Nordenberg; Claudette Rabinowitz; Baruch Rinkevich; Tania Zehavi; Meir Lahav
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

3.  Selective killing of Burkitt's lymphoma cells by mBAFF-targeted delivery of PinX1.

Authors:  L Zhang; Y Jiang; Y Zheng; Y Zeng; Z Yang; G Huang; D Liu; M Gao; X Shen; G Wu; X Yan; F He
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

Review 4.  Telomerase and drug resistance in cancer.

Authors:  Natalia Lipinska; Aleksandra Romaniuk; Anna Paszel-Jaworska; Ewa Toton; Przemyslaw Kopczynski; Blazej Rubis
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

5.  Overexpression of MiR-138 Inhibits Cell Growth and Induces Caspase-mediated Apoptosis in Acute Promyelocytic Leukemia Cell Line.

Authors:  Rima Manafi Shabestari; Fatemeh Alikarami; Davood Bashash; Mostafa Paridar; Majid Safa
Journal:  Int J Mol Cell Med       Date:  2018-03-31

6.  Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses.

Authors:  Lakshmi S; Shanitha A; Shiny Dv; Rahul Bs; Saikant R; Shehna Sharaf; Abi Sa; Rajmohan G
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.